Singapore, Jan. 28 -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developedGLP-1class obesity and metabolic disease treatment.Hanmi Pharmaceutical, the core operating company of Hanmi Science, has signed an exclusive distribution agreement with Mexican pharmaceutical company Laboratorios Sanfer for efpeglenatide, itsGLP-1obesity therapy, as well as the Dapalon Family, Hanmi's flagship diabetes treatment portfolio (Dapalon Tab. and Dapalon Duo SR Tab.).

Under the agreement, Hanmi will supply efpeglenatide and the Dapalon Family, while Laboratorios Sanfer will be responsible for regulatory approval, marketing, distribution, and sales withinMexico.

Mexicois one of the countries with the high...